导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -11.37% | 3891/4773 |
| 近一周 | -3.96% | 4377/5458 |
| 近一月 | -0.42% | 890/5421 |
| 近一季 | 0.98% | 780/5205 |
| 近半年 | -0.03% | 1386/4920 |
| 近一年 | -22.24% | 3999/4361 |
| 近两年 | 100.10% | 614/2954 |
| 近三年 | 60.24% | 446/2253 |
| 成立以来 | 81.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-16.57% 4747/4961 |
5.07% 2891/5312 |
- - |
- - |
| 2025 | 37.50% 895/4813 |
1.78% 1551/3635 |
20.72% 13/4076 |
28.16% 1279/4524 |
-12.68% 4267/4813 |
| 2024 | 44.44% 2/3463 |
-12.15% 2449/2808 |
-0.54% 784/3014 |
47.90% 4/3129 |
11.78% 201/3463 |
| 2023 | -4.08% 662/2656 |
1.20% 1615/2280 |
-0.86% 423/2385 |
0.81% 338/2515 |
-5.15% 1272/2655 |
| 2022 | -17.36% 579/2207 |
-15.11% 1022/1919 |
4.62% 991/2016 |
-19.52% 1784/2113 |
15.62% 67/2208 |
| 2021 | 5.07% 557/1822 |
2.24% 223/1255 |
-0.57% 1143/1330 |
4.95% 307/1466 |
-1.52% 1371/1822 |
| 2020 | - - |
- - |
9.85% 780/1067 |
6.13% 871/1164 |
3.90% 884/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 易方达中证香港证券投资ETF VS. 长安沪深300非周期A(740101) |